Brown Advisory’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$35.7M Sell
256,313
-16,221
-6% -$2.27M 0.06% 234
2025
Q4
$33.5M Sell
272,534
-2,294
-0.8% -$279K 0.05% 251
2025
Q3
$30.5M Buy
274,828
+18,289
+7% +$2.08M 0.04% 269
2025
Q2
$28.4M Sell
256,539
-17,362
-6% -$1.85M 0.04% 268
2025
Q1
$30.7M Sell
273,901
-3,372
-1% -$348K 0.04% 247
2024
Q4
$25.6M Sell
277,273
-13,778
-5% -$1.24M 0.03% 303
2024
Q3
$24.4M Buy
291,051
+31,629
+12% +$2.41M 0.03% 307
2024
Q2
$17.8M Buy
259,422
+6,282
+2% +$419K 0.02% 333
2024
Q1
$18.5M Buy
253,140
+29,588
+13% +$2.28M 0.02% 332
2023
Q4
$18.1M Sell
223,552
-20,825
-9% -$1.62M 0.03% 333
2023
Q3
$18.3M Sell
244,377
-3,220
-1% -$248K 0.03% 324
2023
Q2
$19.1M Sell
247,597
-8,275
-3% -$660K 0.03% 319
2023
Q1
$21.2M Buy
255,872
+15,324
+6% +$1.27M 0.04% 302
2022
Q4
$20.7M Sell
240,548
-603
-0.3% -$47.8K 0.04% 308
2022
Q3
$14.9M Buy
241,151
+40,299
+20% +$2.54M 0.03% 341
2022
Q2
$12.4M Buy
200,852
+3,901
+2% +$242K 0.02% 352
2022
Q1
$11.7M Buy
196,951
+14,593
+8% +$933K 0.02% 369
2021
Q4
$13.2M Buy
182,358
+5,308
+3% +$366K 0.02% 369
2021
Q3
$12.4M Buy
177,050
+26,484
+18% +$1.86M 0.02% 351
2021
Q2
$10.4M Buy
150,566
+2,080
+1% +$139K 0.02% 375
2021
Q1
$9.6M Sell
148,486
-413
-0.3% -$26.6K 0.02% 358
2020
Q4
$8.68M Sell
148,899
-25,007
-14% -$1.51M 0.02% 360
2020
Q3
$11M Sell
173,906
-15,491
-8% -$1.07M 0.02% 303
2020
Q2
$14.6M Buy
189,397
+3,401
+2% +$261K 0.03% 259
2020
Q1
$13.9M Buy
185,996
+46,841
+34% +$3.24M 0.04% 243
2019
Q4
$9.04M Buy
139,155
+23,800
+21% +$1.55M 0.02% 336
2019
Q3
$7.31M Buy
115,355
+12,099
+12% +$791K 0.02% 356
2019
Q2
$6.97M Sell
103,256
-19,065
-16% -$1.25M 0.02% 370
2019
Q1
$7.95M Buy
122,321
+22,348
+22% +$1.49M 0.02% 387
2018
Q4
$6.25M Buy
99,973
+44,785
+81% +$3.13M 0.02% 386
2018
Q3
$4.26M Sell
55,188
-5,212
-9% -$394K 0.01% 478
2018
Q2
$4.28M Buy
60,400
+203
+0.3% +$14.3K 0.01% 473
2018
Q1
$4.54M Buy
60,197
+8,006
+15% +$636K 0.01% 409
2017
Q4
$3.74M Sell
52,191
-1,469
-3% -$112K 0.01% 446
2017
Q3
$4.35M Sell
53,660
-4,080
-7% -$312K 0.01% 416
2017
Q2
$4.09M Sell
57,740
-19,951
-26% -$1.33M 0.01% 436
2017
Q1
$5.28M Sell
77,691
-82,028
-51% -$5.77M 0.02% 366
2016
Q4
$11.4M Sell
159,719
-23,796
-13% -$1.77M 0.04% 270
2016
Q3
$14.5M Sell
183,515
-22,743
-11% -$1.85M 0.05% 241
2016
Q2
$17.2M Sell
206,258
-7,772
-4% -$690K 0.06% 215
2016
Q1
$19.7M Buy
214,030
+3,687
+2% +$332K 0.07% 184
2015
Q4
$21.3M Sell
210,343
-1,273
-0.6% -$132K 0.07% 188
2015
Q3
$20.8M Sell
211,616
-3,658,795
-95% -$406M 0.07% 182
2015
Q2
$453M Sell
3,870,411
-1,030,225
-21% -$113M 1.48% 24
2015
Q1
$481M Sell
4,900,636
-1,589,263
-24% -$161M 1.53% 23
2014
Q4
$612M Sell
6,489,899
-1,526,800
-19% -$158M 1.93% 14
2014
Q3
$853M Sell
8,016,699
-544,731
-6% -$53.3M 2.74% 7
2014
Q2
$710M Sell
8,561,430
-123,795
-1% -$9.64M 2.23% 12
2014
Q1
$615M Buy
8,685,225
+2,427,568
+39% +$190M 1.96% 17
2013
Q4
$470M Buy
6,257,657
+6,228,123
+21,088% +$434M 1.52% 27
2013
Q3
$1.86M Buy
29,534
+2,695
+10% +$161K 0.01% 435
2013
Q2
$1.38M Buy
+26,839
New +$1.4M 0.01% 430

Other funds holding GILD

Brown Advisory's GILD Position: Q1 2026 in Review

Brown Advisory reduced its Gilead Sciences (GILD) stake by 6% in Q1 2026, selling an estimated $2.27M and leaving 256,313 shares worth $35.7M. The position accounts for 0.06% of the portfolio, ranked #234.

Brown Advisory first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $853M in Q3 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Brown Advisory held 256,313 shares of Gilead Sciences worth $35.7M as of Q1 2026.
  • Brown Advisory sold 16,221 Gilead Sciences shares in Q1 2026, an estimated $2.27M.
  • Gilead Sciences made up 0.06% of Brown Advisory's portfolio in Q1 2026, its #234 holding.
  • Brown Advisory first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Brown Advisory's Gilead Sciences position peaked at $853M in Q3 2014.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Brown Advisory's 13F filing for Q1 2026, filed 15 May 2026.